ReviewProgress in molecular biology and translational science2011
Probing human cardiovascular congenital disease using transgenic mouse models.
Review in Progress in molecular biology and translational science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Identifying links between cardiovascular disease and insomnia by modeling genes from a pleiotropic locus.Disease models & mechanisms · 2025Article
- Ungated, plug-and-play preclinical cardiac CEST-MRI using radial FLASH with segmented saturation.Magnetic resonance in medicine · 2025Article
- Realistic Aspects of Cardiac Ultrasound in Rats: Practical Tips for Improved Examination.Journal of imaging · 2024Review
- Technologies to Study Genetics and Molecular Pathways.Advances in experimental medicine and biology · 2024Review
- Congenital Heart Defects and 22q11.2 Deletion Syndrome: A 20-Year Update and New Insights to Aid Clinical Diagnosis.Journal of pediatric genetics · 2023Review
- DysregulatedeLife · 2022Article
- Genetic mouse models of autism spectrum disorder present subtle heterogenous cardiac abnormalities.Autism research : official journal of the International Society for Autism Research · 2022Article
- Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.Journal of the Endocrine Society · 2021Article
- High-speed, high-frequency ultrasound, in utero vector-flow imaging of mouse embryos.Scientific reports · 2017Article
- Knock-in mice harboring a Ca(2+) desensitizing mutation in cardiac troponin C develop early onset dilated cardiomyopathy.Frontiers in physiology · 2015Article
- Murine fetal echocardiography.Journal of visualized experiments : JoVE · 2013Article
- Cardiac-specific inducible and conditional gene targeting in mice.Circulation research · 2012Review
- Transforming growth factor Beta2 is required for valve remodeling during heart development.Developmental dynamics : an official publication of the American Association of Anatomists · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Congenital heart defects (CHDs) impact in utero embryonic viability, children, and surviving adults. Since the first transfer of genes into mice, transgenic mouse models have enabled researchers to experimentally study and genetically test the roles of genes in development, physiology, and disease progression. Transgenic mice have become a bona fide human CHD pathology model and their use has dramatically increased within the past two decades. Now that the entire mouse and human genomes are known, it is possible to knock out, mutate, misexpress, and/or replace every gene. Not only have transgenic mouse models changed our understanding of normal development, CHD processes, and the complex interactions of genes and pathways required during heart development, but they are also being used to identify new avenues for medical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.